tetano
Editor, Senior Moderator
J Infect Dis. 2020 Apr 29. pii: jiaa228. doi: 10.1093/infdis/jiaa228. [Epub ahead of print]
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients.
Zeng QL[SUP]1[/SUP], Yu ZJ[SUP]1[/SUP], Gou JJ[SUP]1[/SUP], Li GM[SUP]2[/SUP], Ma SH[SUP]2[/SUP], Zhang GF[SUP]3[/SUP], Xu JH[SUP]4[/SUP], Lin WB[SUP]5[/SUP], Cui GL[SUP]6[/SUP], Zhang MM[SUP]2[/SUP], Li C[SUP]2[/SUP], Wang ZS[SUP]7[/SUP], Zhang ZH[SUP]1[/SUP], Liu ZS[SUP]1[/SUP].
Author information
Abstract
Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19); Fatality; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Survival rate; Viral shedding
PMID:32348485DOI:10.1093/infdis/jiaa228
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients.
Zeng QL[SUP]1[/SUP], Yu ZJ[SUP]1[/SUP], Gou JJ[SUP]1[/SUP], Li GM[SUP]2[/SUP], Ma SH[SUP]2[/SUP], Zhang GF[SUP]3[/SUP], Xu JH[SUP]4[/SUP], Lin WB[SUP]5[/SUP], Cui GL[SUP]6[/SUP], Zhang MM[SUP]2[/SUP], Li C[SUP]2[/SUP], Wang ZS[SUP]7[/SUP], Zhang ZH[SUP]1[/SUP], Liu ZS[SUP]1[/SUP].
Author information
Abstract
Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19); Fatality; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Survival rate; Viral shedding
PMID:32348485DOI:10.1093/infdis/jiaa228